The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIlika Plc Regulatory News (IKA)

Share Price Information for Ilika Plc (IKA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 30.50
Bid: 29.00
Ask: 32.00
Change: 0.50 (1.67%)
Spread: 3.00 (10.345%)
Open: 30.50
High: 31.00
Low: 29.50
Prev. Close: 30.00
IKA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Key Technology Development Milestone

20 Nov 2023 07:00

RNS Number : 8931T
Ilika plc
20 November 2023
 

Ilika plc

("Ilika" or the "Company")

 

Achievement of Key Technology Development Milestone

 

Ilika development team reaches design-freeze milestone for first customer prototype release of Goliath battery.

 

Ilika (AIM: IKA), a pioneer in solid state battery technology, announces it has achieved its D4 development point, which is a design-freeze milestone in the Goliath roadmap upon which Ilika's first prototype for customer release, P1, is based. The P1 prototype is an intermediate milestone on Ilika's roadmap to its minimum viable product (MVP) in 2025. The P1 Goliath prototype is a solid-state pouch cell with an NMC cathode and a silicon anode.

 

The D4 development point is an important milestone for the Company, effectively marking the start of Goliath's productization journey, being the essential marker for the P1 prototype. The D4 development point means that a number of key data sets - including energy density and power density have been met while showing that the Company is firmly on track to achieve lithium-ion energy parity by the end of the current calendar. Given the data sets that are now achievable the Company will be able to create P1 samples, which comprise four layer stacks, for sale to OEMs for testing.

 

Over the next six months, Ilika will manufacture and test batches of pouch cells based on the D4 development point prior to delivering fully characterized P1 cells to up to 15 customers in 2024. Ilika is currently in discussions with its customer base for Goliath batteries, which is primarily automotive OEMs, but also includes Tier 1 automotive suppliers and consumer appliance companies.

 

Work is continuing on Ilika's roadmap through to MVP, for which the corresponding D8 development point will be achieved at the end of 2024. The MVP, or P2 prototypes will be stackable to 30 layers, underpinning licensing opportunities. Further detail re the product curve and development points can be found on page 11 of the Company's 2023 Annual Report, which is available by clicking here.

 

Graeme Purdy, Ilika CEO, stated: "Achieving our D4 development point is an important milestone on our technology roadmap, as it forms the basis of our first prototype product pilot run, with the objective of sharing prototypes with our customer base in 2024. This achievement is a clear demonstration that the Ilika team is working very efficiently with the available resources to achieve credible outcomes for our customers within the ambitious timeframes that we have set."

 

 

 

For more information contact:

Ilika plc

www.ilika.com

Graeme Purdy, Chief Executive

Via Walbrook PR

Jason Stewart, Chief Financial Officer

Liberum Capital Limited (Nomad and Joint Broker)

Tel: 020 3100 2000

Andrew Godber,

Nikhil Varghese

Joh. Berenberg, Gossler & Co. KG (Joint Broker)

Tel: 020 3207 8700

Matthew Armitt, Mark Whitmore, Detlir Elezi,

Natasha Ninkov

Walbrook PR Ltd

Tel: 020 7933 8780 / Ilika@walbrookpr.com

Nick Rome

Mob: 07748 325 236

 

About Ilika plc - https://www.ilika.com

Ilika specialises in the developing and commercialisation of solid state batteries. The Company's mission is to rapidly develop leading-edge IP, manufacture and license solid state batteries for markets that cannot be addressed with conventional batteries due to their safety, charge rates, energy density and life limits. The Company achieves this by using ceramic-based lithium-ion technology that is inherently safe in manufacture and usage, higher thermal tolerance and easier to recycle which differentiates our products from existing batteries.

 

The Company has two product lines. Its Stereax batteries which are designed for powering miniature medical implants, industrial wireless sensors and specialist internet of Things (IoT) applications and the Goliath large format batteries designed for EV cars and cordless appliances.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDDLFFXFLXFBB
Date   Source Headline
26th Apr 20247:00 amRNSAgratas joins Goliath industrialisation programme
23rd Apr 20247:00 amRNSCapital Markets Day and Trading Update
27th Mar 20247:00 amRNSNotice of Capital Markets Day and Investor Q&A
23rd Jan 20247:00 amRNSHalf-year Report
15th Jan 20247:00 amRNS2024 Conference Schedule
14th Dec 20231:46 pmRNSAward of Share Options, Exercise of Options & TVR
13th Dec 20231:43 pmRNSHolding(s) in Company
6th Dec 20237:00 amRNSLithium-ion parity development milestone
24th Nov 20237:00 amRNSTrading Update, Notice of Results & Presentations
20th Nov 20237:00 amRNSKey Technology Development Milestone
9th Oct 20237:00 amRNSAward of Scale-up Grant Funding for Goliath
20th Sep 20233:20 pmRNSResult of AGM & Award of Executive Share Options
18th Aug 20237:00 amRNSPosting of Annual Report and Notice of AGM
4th Aug 20237:00 amRNSSigned agreement with Cirtec Medical
13th Jul 20237:00 amRNSFinal Results
16th Jun 20237:00 amRNSSenior appointment&conversion of preference shares
22nd May 20237:00 amRNSTrading Update & Notice of Results
11th May 20237:00 amRNSFirst Customer Shipments of Stereax M300 Batteries
26th Apr 20237:00 amRNSExercise of Options and Total Voting Rights
11th Apr 20237:00 amRNSFirst Customer Shipment of Stereax® Batteries
8th Mar 20234:35 pmRNSPrice Monitoring Extension
1st Mar 20237:00 amRNSAward of Share Options
31st Jan 202310:30 amRNSDirector/PDMR Shareholding
30th Jan 20232:05 pmRNSSecond Price Monitoring Extn
30th Jan 20232:00 pmRNSPrice Monitoring Extension
30th Jan 202311:05 amRNSSecond Price Monitoring Extn
30th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20232:05 pmRNSSecond Price Monitoring Extn
26th Jan 20232:00 pmRNSPrice Monitoring Extension
26th Jan 202311:05 amRNSSecond Price Monitoring Extn
26th Jan 202311:00 amRNSPrice Monitoring Extension
26th Jan 20239:05 amRNSSecond Price Monitoring Extn
26th Jan 20239:00 amRNSPrice Monitoring Extension
26th Jan 20237:00 amRNSAward of Grant Funding for Goliath
19th Jan 20237:00 amRNSHalf-year Report
16th Jan 20237:00 amRNSMOU signed with Cirtec Medical
9th Jan 20234:40 pmRNSSecond Price Monitoring Extn
9th Jan 20234:35 pmRNSPrice Monitoring Extension
28th Dec 20224:40 pmRNSSecond Price Monitoring Extn
28th Dec 20224:35 pmRNSPrice Monitoring Extension
28th Dec 20222:05 pmRNSSecond Price Monitoring Extn
28th Dec 20222:00 pmRNSPrice Monitoring Extension
19th Dec 20224:40 pmRNSSecond Price Monitoring Extn
19th Dec 20224:35 pmRNSPrice Monitoring Extension
16th Dec 20224:40 pmRNSSecond Price Monitoring Extn
16th Dec 20224:35 pmRNSPrice Monitoring Extension
21st Nov 20221:29 pmEQSIlika 'well positioned' to deliver battery product combination
17th Nov 20224:40 pmRNSSecond Price Monitoring Extn
17th Nov 20224:35 pmRNSPrice Monitoring Extension
17th Nov 20229:05 amRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.